Research Capsules

July 2007
Pharmaceutical Representative;Jul2007, Vol. 37 Issue 7, p13
The article reports on several pharmaceutical studies in the U.S. A double blind study suggests that Wyeth Pharmaceuticals' Pristiq (desvenlafaxine) may benefit women with menopause-related hot flashes. A double blind research shows that New York-based Pfizer Inc.'s pregabalin Lyrica may provide significant symptom relief to fibromyalgia patients. New Jersey-based Novartis Pharmaceuticals Corp.'s Reclast (zoledronic acid) may decrease the incidence of bone fractures in postmenopausal women.


Related Articles

  • Pharmaceuticals.  // Chemical Market Reporter;8/28/2006, Vol. 270 Issue 7, p18 

    The article presents news briefs on the pharmaceutical industry in the U.S. Eli Lilly & Co. has received an approval notice from the Food and Drug Administration for ruboxistaunn mesylate. Novartis Pharmaceuticals Corp. has submitted an application for approval for its drug Galvus to the...

  • Recalls & Warnings.  // Journal of Psychosocial Nursing & Mental Health Services;Jul2005, Vol. 43 Issue 7, p51 

    Presents an update on drug recalls and warnings from pharmaceutical companies in the U.S. Dermatological reactions reported in both children and adults taking Trileptal (oxcarbazepine) from Novartis Pharmaceuticals Corp.; Number of bottles of Neurontin recalled by Pfizer Inc.

  • Industry shifts focus to immunology and cancer. Ledford, Heidi // Nature;11/6/2008, Vol. 456 Issue 7218, p-1 

    The article reports that large drug manufacturers such as Wyeth Pharmaceuticals and Pfizer are shifting their research and development efforts to speciality drugs prescribed by specialists in fields like oncology and neurology. The companies are launching cost control efforts as their...

  • Grand Experiment. Svoboda, Elizabeth // Fast Company;Feb2009, Issue 132, p36 

    The article discusses Wyeth BioPharma (WB), a business unit of Wyeth Pharmaceuticals (WP). WB’s focus on biotechnology has produced some of WP’s most profitable drugs. WP president Mike Karmarck asserts that within two years over half of his firm’s revenue will derive from...

  • The Biomarker Gamble. Koppal, Tanuja // Drug Discovery & Development;Sep2004, Vol. 7 Issue 9, p9 

    The article brings together the heads of biomarker discovery programs at three major pharmaceutical companies, that is, GlaxoSmithKline PLC, Pfizer Inc., and Novartis Pharmaceuticals Corp. Although the approaches at the three companies are different, it is clear that the pharmaceutical industry...

  • NEWS.  // Pharmaceutical Technology Europe;Oct2004, Vol. 16 Issue 10, p7 

    The article presents a discussion on recent developments that have taken place in various pharmaceutical enterprises. According to a study, Novartis Pharmaceutical Corp.'s drug Prexige has demonstrated a significant reduction in the incidence of definite or probable upper gastrointestinal ulcer...

  • Three of the industry's top players post impressive 2004 returns.  // PharmacoEconomics & Outcomes News;1/29/2005, Issue 470, p10 

    Reports on the profits posted by several pharmaceutical companies in the U.S. for the 2004 full-year earnings. Pfizer; Abbott Laboratories; Novartis.

  • Data Integration Serves a Clinical Trial Need for Speed. Keating, Sean // Drug Discovery & Development;Nov2004, Vol. 7 Issue 11, p61 

    Reports on how different pharmaceutical companies and contract research organizations are managing their global clinical trials. Capability of Wyeth Pharmaceuticals' E-Clinical system to review reports on clinical trials and handle all information associated with a clinical trial; Advantages of...

  • Euro tie-up.  // Nature;12/13/2007, Vol. 450 Issue 7172, p935 

    The article reports on the extended partnership of Novartis Pharmaceuticals Corp., A Swiss drug firm with MorphoSys AG, a German biotechnology company, stating it will pay $600 million over 10 years as to help the company discover and develop antibody-based medicines. It added that if MorphoSys...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics